Figure - PMC

Skip to main content

An official website of the United States government

Here's how you know

Here's how you know

Official websites use .gov
A .gov website belongs to an official government organization in the United States.

Secure .gov websites use HTTPS
A lock ( ) or https:// means you've safely connected to the .gov website. Share sensitive information only on official, secure websites.

View full-text article in PMC

. 2016 Apr 12;2(1):1–20. doi: 10.1007/s41048-016-0021-8

Search in PMC
Search in PubMed
View in NLM Catalog
Add to search

© The Author(s) 2016

Open AccessThis article is distributed under the terms of the Creative Commons Attribution 4.0 International License (http://creativecommons.org/licenses/by/4.0/), which permits unrestricted use, distribution, and reproduction in any medium, provided you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made.

PMC Copyright notice

Fig. 10 — Linear relationship between the %ID/cm³ tumor uptake change at days 1 (top), 4 (middle) and 11 (bottom) after linifanib therapy and the expression levels of the α_vβ₃ (left) and CD31 (right) in three tumor-bearing animal models. The %ID/cm³ tumor uptake values of ^99mTc-3P-RGD₂ were calculated from SPECT/CT quantification and reported as the mean plus/minus standard error of the mean based on results from five animals (n = 5). The %ID/cm³ tumor uptake change was calculated by deducting the %ID/cm³ tumor uptake of ^99mTc-3P-RGD₂ on days 1, 4, and 11 from its original value on −1 day (before linifanib therapy) in the same animal. The average %ID/cm³ tumor uptake change is used as the indicator of tumor response to linifanib treatment. The experimental data were adapted from Zheng et al. (2014)